ArticlePlastic and reconstructive surgery. Global open2025
Analysis of Dermal Thickness Across 10 Areas and Injection Depth After Polynucleotide Injection Using Rejumate Automatic 0.8-mm 9-pin Injector on the Face Using 33-MHz Sonography.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Automated injection devices are becoming essential tools in aesthetic medicine, offering precision and consistency in treatments such as polynucleotide (PN) injections for skin rejuvenation. This study aimed to analyze the dermal thickness across facial regions and evaluate the consistency of injection depth achieved with the Rejumate automatic injector. Methods: A total of 31 patients (average age 48.2 y; 4 men and 27 women) underwent dermal thickness measurements using high-resolution 33-MHz ultrasound in 11 facial regions, including the forehead, temple, orbital rim, lower eyelid, malar, anterior cheek, lateral cheek, posterior cheek, jawline, and chin. Each patient then received a standardized 2-mL PN injection using the Rejumate injector with a 0.8-mm needle across 317 individual points. Injection depth, distribution, and consistency were measured and analyzed. Results: The average dermal thickness across regions ranged from 0.53 (lower eyelid) to 1.18 mm (temple and posterior cheek). The Rejumate injector demonstrated a high degree of consistency, achieving an average injection depth of 0.55 mm (SD = 0.13 mm), with a median depth of 0.54 mm. The depth range (0.29-0.99 mm) and interquartile range (0.17 mm) indicated controlled depth with minimal variability. Conclusions: The Rejumate automatic injector reliably delivers PN at a controlled depth, showing minimal variability across injections. This precision supports improved safety and efficacy in PN delivery, providing a valuable reference for clinical application in aesthetic treatments. Given the anatomical differences in dermal thickness across facial regions, this standardized approach may optimize outcomes and increase patient satisfaction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.